View all newsletters
Receive our newsletter - data, insights and analysis delivered to you
  1. Comment
January 28, 2021

Myocarditis: A potentially dangerous aftereffect from Covid-19

By GlobalData Healthcare

Covid-19 has many potential sequelae, secondary conditions directly resulting from the infection. Perhaps one of the most concerning is myocarditis, which is defined as inflammation of the heart muscle and is commonly associated with a viral infection, according to the American Heart Association.

Free Report
img

Build resilience in the face of COVID-19 disruption

COVID-19 has already affected our lives forever. The way we work, shop, eat, seek medical advice, and socialize will all be different in the future. Quite how different remains to be seen, but all industries must plan for multiple eventualities. Are you interested in actionable insights on the business challenges induced by the pandemic? GlobalData's cross-sector report analyzes the significance of this major disruptive theme across industry verticals. It provides side-by-side research of alternative datasets to present you with unique quantitative analysis of the effects of COVID-19 and how these differ across sectors. Additionally, it offers qualitative analysis of each sector and analyzes COVID-19’s impact on leading companies. Whatever your company’s imminent strategic plans, the long-lasting impact of COVID-19 must not be overlooked. Find out how to futureproof your business operations – download our report today.
by GlobalData
Enter your details here to receive your free Report.

The Mayo Clinic indicates that common symptoms of myocarditis can include chest pain and shortness of breath, as well as arrhythmias and fatigue. In more severe cases, myocarditis can lead to heart failure, a heart attack, stroke, and even sudden cardiac arrest. While the connection between Covid-19 and myocarditis has not been identified, several theories are currently being studied and point to either the virus itself or potentially the immune response to the virus. There is physiological credence to both theories. In the former, a study published in September 2020 by Siripanthong and colleagues in Heart Rhythm indicates that the virus can enter heart tissue through the ACE2 receptor. In the latter, a review article by Tschöpe and colleagues published in Nature a month later argues that the adaptive immune system’s response to SARS-CoV-2 infection can result in inflammation to the heart muscle. Both theories, however, need further evaluation in relation to Covid-19.

The incidence of Covid-19-induced myocarditis is not well established. In late July, shocking findings from a study published in JAMA Cardiology suggested that after being screened via cardiac magnetic resonance imaging, 60% of Covid-19 survivors (independent of the severity of the illness) had developed myocarditis. Moreover, a later study also published in JAMA showed that 12 of 26 athletes had indications of either current or past myocarditis. Given the vast amount of Covid-19 cases that are asymptomatic to moderate, if these findings are to be extrapolated to the general population, then there are likely many cases among individuals who may not know they are at risk. This is particularly relevant for young adults, who are more likely to develop myocarditis and less likely to develop a severe case of the disease.

Evidence to suggest that myocarditis develops after Covid-19 and its incidence need to be further investigated, however. Myocarditis is challenging to diagnose, making it challenging to systematically approximate incidence among Covid-19 survivors. Given the rising case numbers, such research and screening among patients experiencing myocarditis symptoms after recovery are of great importance to prevent and mitigate further complications.

Related Companies

Free Report
img

Build resilience in the face of COVID-19 disruption

COVID-19 has already affected our lives forever. The way we work, shop, eat, seek medical advice, and socialize will all be different in the future. Quite how different remains to be seen, but all industries must plan for multiple eventualities. Are you interested in actionable insights on the business challenges induced by the pandemic? GlobalData's cross-sector report analyzes the significance of this major disruptive theme across industry verticals. It provides side-by-side research of alternative datasets to present you with unique quantitative analysis of the effects of COVID-19 and how these differ across sectors. Additionally, it offers qualitative analysis of each sector and analyzes COVID-19’s impact on leading companies. Whatever your company’s imminent strategic plans, the long-lasting impact of COVID-19 must not be overlooked. Find out how to futureproof your business operations – download our report today.
by GlobalData
Enter your details here to receive your free Report.

NEWSLETTER Sign up Tick the boxes of the newsletters you would like to receive. Key drug pipeline and competitive landscape changes based on the latest clinical activity, sent every Tuesday. Curated analysis and data-driven insights on clinical trials strategy and operations, sent every Thursday. The pharmaceutical industry's most comprehensive news and information delivered every month.
I consent to GlobalData UK Limited collecting my details provided via this form in accordance with the Privacy Policy
SUBSCRIBED

THANK YOU

Thank you for subscribing to Clinical Trials Arena